Stop VTE Prophylaxis at Discharge for Most COVID-19 Patients

New data will spark debate about the role of postdischarge venous thromboembolism (VTE) prophylaxis in COVID-19 patients.

We know that COVID-19 patients should receive VTE prophylaxis while hospitalized...which typically stops at discharge.

Now data suggest rivaroxaban (Xarelto) 10 mg daily for 35 days postdischarge in COVID-19 patients with HIGH clotting and LOW bleeding risk reduces VTE...without increasing bleeding.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 120+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote